Apple Wins $700 After-the-Bell and 4 Stocks Riding 52-Week Highs

Apple Inc. (NASDAQ:AAPL): Wi-LAN has given a litigation update concerning the consolidation of two cases to be held before the U.S. District Court for the Eastern District of Texas, Tyler and Marshall Divisions respectively. Both cases are concerned with the infringement of WiLAN’s Patent No. RE37,802 related to CDMA and HSPA and U.S. Patent No. 5,282,222 related to Wi-Fi and LTE. On September 14, the Court gave WiLAN permission to transfer the case from the Tyler Division to the Marshall Division, which led to the advancement of the Apple case trial date by eight months. The trial date that has been set for the consolidated Apple and HTC cases should be August 5, 2013. The shares closed at $699.78, up $8.5 or 1.23% on the day. They have traded in a 52-week range of $354.24 to $696.98.

Don’t Miss: Can Apple Sell ALL These iPhones This Month?

Alliance Data System’s (NYSE:ADS) Retail Services business should begin providing private label credit card services for multichannel retailer The Talbots, which is a wholly owned subsidiary of Sycamore Partners’ TLB Holdings. Additionally, Alliance Data has acquired the receivables from Talbots’ existing private label credit card file, and it plans to acquire the credit card accounts, which currently has pending regulatory approval. Alliance Data entered into agreements with The Talbots, subject to regulatory approval, for the management of their private label credit card program and for the purchase of the retailer’s existing credit card accounts. Beneath these agreements, Alliance Data has gained the receivables related to the portfolio of about $145 million. The shares closed at $142.53, up $1.62 or 1.15% on the day. They have traded in a 52-week range of $84.91 to $142.92.

Ariad Pharmaceutical’s (NASDAQ:ARIA)  initial data from its Phase 1/2 trial of AP26113, which is an investigational dual inhibitor of anaplastic lymphoma kinase and epidermal growth factor receptor, is set to be presented at the ESMO 2012 Congress of the European Society for Medical Oncology which is to take place in Vienna, Austria, on September 28 to October 2. Results from the dose-escalation portion of the ongoing Phase 1/2 trial are to be revealed and discussed via an oral presentation on Saturday, September 29. The shares closed at $23.50, up $0.34 or 1.47% on the day. They have traded in a 52-week range of $7.72 to $23.30.

Briggs & Stratton (NYSE:BGG) will temporarily shut down its production facility in McDonough, Georgia to lower inventory levels of lawn and garden products that produced at the facility. Lawn and garden equipment’s market demand sees continued softness due to the constant drought affecting a great deal of the U.S. since May. Production is to be halted from October 29 to November 25, but shipments of products and service parts to customers should continue. Additionally, plant personnel is to use the shutdown period for the completion of the movement of some equipment from the Company’s recently closed facility located in Newbern, TN into the McDonough plant as it also re-tools for new products for spring production. This will cause nearly 340 hourly employees and 200 temporary employees to be temporarily laid off, and the company does not believe that it will see any large impact to its FY13 net income of $60 million to $75 million, or $1.25-$1.55 per diluted share caused by this temporary plant shutdown. The shares closed at $19.63, down $0.09 or 0.46% on the day. They have traded in a 52-week range of $12.36 to $19.74.

Chevron Corp. (NYSE:CVX): Oil has been trading close to its four-month high, prior to reports able to show improvement to U.S. economic growth, according to Bloomberg. In New York, little changed after the price moved up to $100.42 a barrel on Friday. The shares closed at $117.14, down $0.11 or 0.09% on the day. They have traded in a 52-week range of $86.68 to $114.54.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

More from The Cheat Sheet